Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Capital Expenditures (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Capital Expenditures for 16 consecutive years, with $611.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 106.63% year-over-year to $611.0, compared with a TTM value of $78415.0 through Sep 2025, up 34.59%, and an annual FY2024 reading of $38411.0, up 233.52% over the prior year.
  • Capital Expenditures was $611.0 for Q3 2025 at China Pharma Holdings, up from -$65.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $415977.0 in Q3 2021 and bottomed at -$55964.0 in Q1 2023.
  • Average Capital Expenditures over 5 years is $60380.6, with a median of $4527.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures plummeted 4123.29% in 2023, then skyrocketed 331.74% in 2024.
  • Year by year, Capital Expenditures stood at $7056.0 in 2021, then tumbled by 486.45% to -$27268.0 in 2022, then surged by 116.6% to $4527.0 in 2023, then soared by 331.74% to $19545.0 in 2024, then tumbled by 96.87% to $611.0 in 2025.
  • Business Quant data shows Capital Expenditures for CPHI at $611.0 in Q3 2025, -$65.0 in Q2 2025, and $58324.0 in Q1 2025.